- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00560066
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
19. Januar 2016 aktualisiert von: Novartis Vaccines
A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture (Optaflu®) or in Embryonated Hen Eggs (Agrippal®) in Adults and Elderly With and Without Underlying Medical Conditions, and to Evaluate the Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
Evaluation of the safety of Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in embryonated Hen Eggs in subjects 18 years of age and above with and without underlying medical conditions and evaluation of the immunogenicity in a subset of subjects with underlying medical conditions, compared to an egg-based vaccine in a post marketing setting.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
1398
Phase
- Phase 4
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Balve, Deutschland
-
Duisberg, Deutschland
-
Garmisch-Partenkirchen, Deutschland
-
Hannover, Deutschland
-
Herborn, Deutschland
-
Illingen, Deutschland
-
Kiel, Deutschland
-
Laufach, Deutschland
-
Marburg, Deutschland
-
Midlum, Deutschland
-
Olpe, Deutschland
-
Potsdam, Deutschland
-
Regensburg, Deutschland
-
Unterschleißheim, Deutschland
-
Wiesbaden, Deutschland
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Subjects 18 years of age and above, mentally competent, willing and able to give informed consent prior to study entry;
- Able to comply with all study procedures and requirements.
Exclusion Criteria:
- History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to any vaccine component;
- Fatal prognosis of an underlying medical condition (<12 months life expectancy);
- History of Guillain-Barre syndrome;
- Bleeding diathesis or receiving anticoagulants of the coumarin type;
- Hospitalization or residence in a nursing care facility;
- Planned to receive seasonal influenza vaccine outside of this study;
- Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study;
- Fever (defined as axillary temperature ≥38.0°C) or any acute illness within 3 days prior to study vaccination;
- Receipt of another investigational agent within 30 days prior to enrollment in the study or before completion of the safety follow-up period in another study, whichever is longer, and unwilling to refuse participation in another clinical study through the end safety follow up period of the study;
- Any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives;
- Females who were pregnant or nursing (breastfeeding) mothers, or females of childbearing potential who were sexually active and had not used or did not plan to use acceptable birth control measures during the first 3 weeks after vaccination. Oral, injected or implanted hormonal contraceptive, diaphragm or condom with spermicidal agent or intrauterine device were considered acceptable forms of birth control.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: cTIV
Subjects received one vaccination of cell culture-derived influenza vaccine
|
1 dose of 0.5 mL in the deltoid region of the non-dominant arm
|
Aktiver Komparator: TIV
Subjects received one vaccination of egg-derived influenza vaccine
|
1 dose of 0.5 mL in the deltoid region of the non-dominant arm
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Subjects Who Reported At Least One Reactogenicity Sign After One Vaccination of TIV or cTIV
Zeitfenster: From Day 1 up to and including Day 7 post-vaccination
|
Safety was assessed as the number of all subjects who reported at least one sign of reactogenicity after one vaccination of egg-derived (TIV) or cell culture-derived (cTIV) influenza virus vaccine from Day 1 through Day 7 post-vaccination.
|
From Day 1 up to and including Day 7 post-vaccination
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Healthy Adults and Elderly Who Reported Solicited Local and Systemic Adverse Events (AEs) After One Vaccination of TIV or cTIV
Zeitfenster: From Day 1 through Day 7 post-vaccination
|
Analysis was performed on a subset of safety population which included the healthy adults (≥18 to ≤60 years) and elderly (≥61 years).
|
From Day 1 through Day 7 post-vaccination
|
Number of Adults and Elderly With Underlying Medical Conditions Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIV or cTIV
Zeitfenster: From Day 1 through Day 7 post-vaccination
|
Analysis was performed on a subset of safety population which included the adults (≥18 to ≤60 years) and elderly (≥61 years) with underlying medical conditions.
|
From Day 1 through Day 7 post-vaccination
|
Percentages Of Subjects With Underlying Medical Conditions Who Achieved Hemagglutination Inhibition (HI) Titer ≥40 After One Vaccination of TIV or cTIV
Zeitfenster: Before vaccination (Day 1) and three weeks after vaccination (Day 22)
|
Immunogenicity was measured as the percentage of adults (≥18 to ≤60 years) and elderly (≥61 years) achieving HI titers ≥40 at baseline (Day 1) and three weeks (Day 22) after one vaccination of TIV or cTIV for each of three vaccine strains, evaluated using hemagglutination inhibition (HI) egg-derived antigen assay.
This criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is >70% (≥18 to ≤60 years), or >60% (≥61 years).
|
Before vaccination (Day 1) and three weeks after vaccination (Day 22)
|
Percentages Of Subjects Who Achieved Seroconversion Or Significant Increase In HI Titers After One Vaccination of TIV or cTIV
Zeitfenster: Three weeks post-vaccination (Day 22)
|
Seroconversion or significant increase in HI titer as per CHMP criteria for each of the three strains is defined as the percentage of subjects with a prevaccination HI titer <10 to a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer.
According to the CHMP criteria, the percentage of subjects achieving seroconversion/significant increase should be >40% (≥18 to ≤60 years) or >30% (≥61 years).
|
Three weeks post-vaccination (Day 22)
|
Geometric Mean Titers of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV
Zeitfenster: Before vaccination (Day 1) and three weeks after vaccination (Day 22)
|
Immunogenicity was measured as HI geometric mean titers (GMTs) of subjects with underlying conditions, directed against each of three vaccine strains at baseline (Day 1) and three weeks after vaccination (Day 22) in adults (≥18 to ≤60 years) and elderly (≥61 years).
|
Before vaccination (Day 1) and three weeks after vaccination (Day 22)
|
Geometric Mean Ratio of Subjects With Underlying Medical Conditions After One Vaccination of TIV or cTIV
Zeitfenster: Three weeks post-vaccination (Day 22)
|
Immunogenicity was measured as the geometric mean ratio (GMR), calculated as the ratio of postvaccination to prevaccination HI GMTs for each of the three strains, three weeks after one vaccination (Day 22) of TIV or cTIV.
CHMP criteria is considered fulfilled for each of the three strains if the geometric mean increase GMR (Day 22/Day 1) in HI antibody titer is >2.5 (≥18 to ≤60 years) or >2.0 (≥61 Years).
|
Three weeks post-vaccination (Day 22)
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. November 2007
Primärer Abschluss (Tatsächlich)
1. Juli 2008
Studienabschluss (Tatsächlich)
1. Juli 2008
Studienanmeldedaten
Zuerst eingereicht
16. November 2007
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
16. November 2007
Zuerst gepostet (Schätzen)
19. November 2007
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
17. Februar 2016
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
19. Januar 2016
Zuletzt verifiziert
1. Januar 2016
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- V58P14
- 2007-002872-32
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Cell-derived influenza vaccine
-
NYU Langone HealthViracor EurofinsNoch keine RekrutierungLungentransplantation; KomplikationenVereinigte Staaten